Hims & Hers Health, Inc. and certain executives face a securities class action in the U.S. District Court for the Northern District of California after the Federal Trade Commission alleged that the telehealth company shared sensitive health information with third-party advertising platforms and misled consumers about billing and cancellation practices. The alleged conduct includes charging consumers for prescriptions almost immediately after they submitted intake forms, before consulting a medical provider, despite statements that consumers could find a treatment that was right for them. Hims shares fell $4.32, or 14.73%, to close at $25.00 on July 29, 2026, after the FTC announcement. The proposed class period covers securities acquired from Aug. 4, 2025, through July 29, 2026, inclusive. Investors seeking appointment as lead plaintiff must apply by Nov. 2, 2026. ClaimsFiler is providing information about the case, Velanki v. Hims & Hers Health, Inc. et al., 26-cv-09313, and directing investors to Kahn Swick & Foti, LLC for legal discussions.